Samenvatting
Type 1 diabetes is often considered as a disease where more than 90% of the beta cells have been destroyed at clinical onset and where beta cell antigen-driven autoimmune reactivities progressively destroy remaining beta cells as well as newly formed or implanted beta cells. This view will be evaluated in light of histological observations in the pancreas of type 1 diabetic patients and of antibody-positive non-diabetic organ donors.
| Originele taal-2 | English |
|---|---|
| Titel | Defining Optimal Immunotherapies for Type 1 Diabetes: Novartis Foundation Symposium |
| Uitgeverij | Wiley |
| Pagina's | 19-24 |
| Aantal pagina's | 5 |
| Volume | 292 |
| Status | Published - 2008 |